Press releasePRNewswire
Agios Pharmaceuticals
AGIO · NASDAQ
$36.64+$1.74 (+4.99%)TodayMarket closed ·
Prev close $34.90
Latest news
- NewsAvi Kapoor
Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
- Press releaseGlobe Newswire
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
- NewsVandana Singh
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
- Press releaseGlobe Newswire
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
- NewsVandana Singh
Why Is Agios Pharma Stock Soaring Tuesday?
- Press releaseGlobe Newswire
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
- Press releaseGlobe Newswire
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
- News
Agios Acquires Global Rights to Experimental Blood Disorder Drug From South Korea's Oscotec
- Press releaseGlobe Newswire
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
- Press releaseGlobe Newswire
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
- Press releaseBusiness Wire
Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
- News
Agios Pharmaceuticals Announces EU Marketing Authorization For PYRUKYND In Adults For Treatment Of Anemia
- Press releaseGlobe Newswire
Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
- Press releaseGlobe Newswire
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
- News
Earnings Scheduled For April 29, 2026
- Press releaseGlobe Newswire
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results
- Press releasePRNewswire
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
- NewsAvi Kapoor
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
- Press releasePRNewswire
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money
- Press releasePRNewswire
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation
- Press releasePRNewswire
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
- Press releasePRNewswire
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation
- Press releasePRNewswire
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
- Press releasePRNewswire
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO
- Press releasePRNewswire
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO
- Press releasePRNewswire
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
- News
Earnings Summary: Agios Pharmaceuticals Q4
- Press releaseGlobe Newswire
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- News
Earnings Scheduled For February 12, 2026
- News
Agios Sets 2026 Growth Plan as FDA-Approved AQVESME Launches and New Trial Readouts Near
- Press releaseGlobe Newswire
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
- NewsAvi Kapoor
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
- NewsVandana Singh
FDA Approves Agios Drug For Thalassemia-Associated Anemia
- NewsAvi Kapoor
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday
- NewsAvi Kapoor
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results
- NewsVandana Singh
Why Is Agios Pharmaceuticals Stock Sinking Today?
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
- News
Earnings Outlook For Agios Pharmaceuticals
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.